Apogee Therapeutics Inc. (NASDAQ:APGE - Get Free Report)'s share price hit a new 52-week high on Wednesday . The stock traded as high as $133.87 and last traded at $133.54, with a volume of 1054062 shares trading hands. The stock had previously closed at $133.50.
Analysts Set New Price Targets
APGE has been the subject of a number of research analyst reports. Wedbush downgraded Apogee Therapeutics from an "outperform" rating to a "neutral" rating and set a $135.00 price target for the company. in a report on Monday, June 22nd. Deutsche Bank Aktiengesellschaft cut Apogee Therapeutics from a "buy" rating to a "hold" rating and raised their price objective for the stock from $116.00 to $135.00 in a research note on Monday, June 22nd. Royal Bank Of Canada boosted their target price on shares of Apogee Therapeutics from $82.00 to $97.00 and gave the company a "sector perform" rating in a research note on Monday, June 8th. TD Cowen cut shares of Apogee Therapeutics from a "buy" rating to a "hold" rating in a report on Tuesday, June 23rd. Finally, Stifel Nicolaus restated a "hold" rating and issued a $135.00 price target (up from $133.00) on shares of Apogee Therapeutics in a research report on Wednesday, June 24th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fifteen have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $121.25.
View Our Latest Analysis on Apogee Therapeutics
Apogee Therapeutics Price Performance
The stock has a market capitalization of $8.27 billion, a price-to-earnings ratio of -30.84 and a beta of 0.32. The company has a 50-day simple moving average of $95.46 and a two-hundred day simple moving average of $82.88.
Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last announced its quarterly earnings results on Monday, May 11th. The company reported ($1.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.07) by $0.01. Research analysts anticipate that Apogee Therapeutics Inc. will post -4.45 EPS for the current year.
Insider Activity
In other Apogee Therapeutics news, CEO Michael Thomas Henderson sold 80,000 shares of the firm's stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $132.54, for a total value of $10,603,200.00. Following the sale, the chief executive officer owned 1,015,987 shares in the company, valued at approximately $134,658,916.98. This trade represents a 7.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Carl Dambkowski sold 26,400 shares of the stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $132.60, for a total value of $3,500,640.00. Following the completion of the transaction, the insider directly owned 179,248 shares of the company's stock, valued at $23,768,284.80. This trade represents a 12.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 162,900 shares of company stock valued at $19,038,985. 24.30% of the stock is owned by insiders.
Hedge Funds Weigh In On Apogee Therapeutics
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. T. Rowe Price Investment Management Inc. boosted its stake in Apogee Therapeutics by 189,522.2% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 2,732,456 shares of the company's stock valued at $206,246,000 after buying an additional 2,731,015 shares in the last quarter. Janus Henderson Group PLC grew its position in Apogee Therapeutics by 324.4% in the fourth quarter. Janus Henderson Group PLC now owns 2,062,604 shares of the company's stock worth $155,697,000 after buying an additional 1,576,626 shares during the last quarter. Perceptive Advisors LLC increased its holdings in shares of Apogee Therapeutics by 72.4% in the fourth quarter. Perceptive Advisors LLC now owns 2,330,651 shares of the company's stock valued at $175,918,000 after buying an additional 978,662 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Apogee Therapeutics by 24.1% in the third quarter. Wellington Management Group LLP now owns 4,723,701 shares of the company's stock valued at $187,673,000 after buying an additional 917,991 shares in the last quarter. Finally, UBS Group AG lifted its position in shares of Apogee Therapeutics by 646.1% during the 3rd quarter. UBS Group AG now owns 799,465 shares of the company's stock valued at $31,763,000 after acquiring an additional 692,308 shares during the last quarter. Institutional investors own 79.04% of the company's stock.
About Apogee Therapeutics
(
Get Free Report)
Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.
The company's lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Apogee Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Apogee Therapeutics wasn't on the list.
While Apogee Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
